BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Crohn's disease clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for Crohn disease: 121 (65 sponsors; 25 newly posted in the last 180 days, 6 stopped in the last 180 days; 18 new-entrant sponsors). Momentum score 21.1, rank 26 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 0, Phase 1 13, Phase 2 29, Phase 3 35, Phase 4 8, N/A 36.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| Janssen Research & Development, LLC | 11 | P3 8, P4 1, P2 1, NA 1 | 1 | 0 |
| Takeda TAK | 14 | P3 7, P2 3, P4 2, NA 2 | 0 | 2 |
| AbbVie ABBV | 14 | NA 6, P3 6, P2 2 | 1 | 1 |
| Eli Lilly and Company LLY | 6 | P2 2, P3 4 | 0 | 0 |
| Hoffmann-La Roche | 4 | P3 3, P2 1 | 0 | 1 |
| Janssen-Cilag Ltd. | 4 | NA 2, P3 2 | 1 | 1 |
| Sanofi SNY | 4 | P1 1, P2 1, P3 2 | 1 | 1 |
| Merck Sharp & Dohme LLC MRK | 2 | P3 2 | 0 | 0 |
| Jiangsu Topcel-KH Pharmaceutical Co., Ltd. | 1 | P3 1 | 0 | 1 |
| Agomab Spain S.L.U. new entrant | 2 | P1 1, P2 1 | 2 | 0 |
| AstraZeneca AZN | 2 | P2 2 | 0 | 0 |
| Biocad | 2 | P2 1, P1 1 | 0 | 1 |
| Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2 | P4 2 | 1 | 0 |
| Direct Biologics, LLC | 2 | P2 2 | 1 | 0 |
| Abivax S.A. ABVX | 1 | P2 1 | 0 | 1 |
| Adacyte Therapeutics SL | 1 | NA 1 | 0 | 0 |
| American Laboratory Products Company AIG | 1 | NA 1 | 0 | 1 |
| Anabio R&D new entrant | 1 | NA 1 | 1 | 0 |
| Anterogen Co., Ltd. | 1 | NA 1 | 0 | 1 |
| AnX Robotica Corp. new entrant | 1 | NA 1 | 1 | 1 |
| Axiom Bioregistry new entrant | 1 | NA 1 | 1 | 0 |
| Benethera (Shaoxing) Biotechnology Co., Ltd. new entrant | 1 | P1 1 | 1 | 1 |
| Biokuris s.a. | 1 | NA 1 | 0 | 0 |
| Celltrion HealthCare France | 1 | NA 1 | 0 | 0 |
| Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | 1 | P1 1 | 0 | 0 |
New-entrant sponsors: Agomab Spain S.L.U., Anabio R&D, AnX Robotica Corp., Axiom Bioregistry, Benethera (Shaoxing) Biotechnology Co., Ltd..
Recently stopped trials
- NCT07222189 Sanofi - terminated: Business decision A Study to Investigate the Long-term Safety, Tolerability and Efficacy of Balinatunfib in Participants With Crohn's Dise
- NCT07250815 Takeda - withdrawn: Sponsor decision A Study on Infections in Adults With Ulcerative Colitis/Crohn's Disease
- NCT06637631 Sanofi - terminated: Business decision. A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.
- NCT05836883 Direct Biologics, LLC - terminated: Enrollment challenges. Study of ExoFlo for the Treatment of Perianal Fistulas
- NCT04173273 Pfizer - terminated: The study was prematurely discontinued due to a lack of efficacy in sub-study 1 A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to S
- NCT03759288 AstraZeneca - terminated: Strategic decision to discontinue the development of brazikumab in inflammatory bowel disease. An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12 est. | P2 | Abivax S.A. ABVX | NCT06456593 Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease | Moderately to Severely Active Crohn Disease | recruiting | 212 |
| 2026-12-17 est. | P2 | Sanofi SNY | NCT06958536 A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's Disease | Crohn's Disease | recruiting | 99 |
| 2026-12-28 est. | P3 | Jiangsu Topcel-KH Pharmaceutical Co., Ltd. | NCT06925594 Phase 3 Study of Human TH-SC01 Cell Injection for Treating Perianal Fistulas in Patients With Crohn's Disease | Crohn's Disease | recruiting | 228 |
| 2026-12-31 est. | P2 | Hoffmann-La Roche | NCT05910528 Afimkibart (RO7790121) for the Treatment of Moderate to Severe Active Crohn's Disease | Crohns Disease | active not recruiting | 21 |
| 2026-12-31 est. | P2 | EL3 Bio, LLC. | NCT07010926 A Double-Blind, Randomized, Placebo-Controlled Phase II Clinical Trial to Evaluate the Safety and Efficacy of L2-01 in Subjects With Crohn's Disease | Crohn&Amp;#39;s; Crohn&Amp;#39;s Disease (CD) | not yet recruiting | 120 |
| 2027-02-17 est. | P2 | Takeda TAK | NCT06233461 A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease | Crohn's Disease | recruiting | 268 |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-10-12 est. | P2 | Jiangsu Carephar Pharmaceutical Co., Ltd. | NCT07677514 A Phase II Study of H021 Enteric-coated Tablets for Moderately to Severely Active Crohn's Disease | Crohn's Disease | not yet recruiting | 156 |
| 2026-09-29 | P2 | Sanofi SNY | NCT07222189 A Study to Investigate the Long-term Safety, Tolerability and Efficacy of Balinatunfib in Participants With Crohn's Disease or Ulcerative Colitis (SPECIFI-IBD-L | Colitis Ulcerative; Crohn's Disease | terminated | 7 |
| 2026-08-15 est. | P2 | Telavant, Inc. | NCT05471492 Study to Evaluate the Efficacy and Safety of PF-06480605 in Adult Participants With Moderate to Severe Crohn's Disease | Crohn Disease | withdrawn | |
| 2026-08-10 | P2 | AstraZeneca AZN | NCT06681324 Study Evaluating AZD7798 for Treatment in Crohn's Disease Patients With an Ileostomy | Crohn's Disease | active not recruiting | 24 |
| 2026-07-30 | P2 | Sanofi SNY | NCT06637631 A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease. | Crohn's Disease | terminated | 105 |
| 2026-06-20 | P2 | Agomab Spain S.L.U. | NCT05843578 STENOVA - A Study to Evaluate Safety, Tolerability, PK and PD of AGMB-129 in Patients With Fibrostenotic Crohn's Disease | Fibrostenotic Crohn's Disease | completed | 103 |
| 2026-06-01 est. | P1/P2 | Intralytix, Inc. | NCT03808103 Safety and Efficacy of EcoActive on Intestinal Adherent Invasive E. Coli in Patients With Inactive Crohn's Disease | Crohn Disease | active not recruiting | 30 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "Crohn disease"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.